Global standard in travel medicine: a risk management ... · Travelers’ vaccines as solutions for...

53
Travelers’ vaccines as solutions for travelers’ risks Global standard in travel medicine: a risk management perspective Robert Steffen

Transcript of Global standard in travel medicine: a risk management ... · Travelers’ vaccines as solutions for...

Page 1: Global standard in travel medicine: a risk management ... · Travelers’ vaccines as solutions for travelers’ risks Global standard in travel medicine: a risk management perspective

Travelers’ vaccines as solutions for travelers’ risks

Global standard in travel medicine: a risk management perspective

Robert Steffen

Page 2: Global standard in travel medicine: a risk management ... · Travelers’ vaccines as solutions for travelers’ risks Global standard in travel medicine: a risk management perspective

Vaccine relevant travel health risks

u Risk: situations — environment, host

u Vaccine preventable diseases: the 4 dimensions

– Incidence rate

– Impact

– Legal aspects

– Financial aspects

u Conclusions

Page 229.02.2012 University of Zurich, Travelers' vaccines, Robert Steffen

Cumulative exposure!

Traveler: death, sequelaePublic health: outbreaks

Page 3: Global standard in travel medicine: a risk management ... · Travelers’ vaccines as solutions for travelers’ risks Global standard in travel medicine: a risk management perspective

Environmental factors à risk profiles

Assess in detailu Destination

– Countries– Urban / rural

u Purpose of travel– Tourism / VFR– Work / business

u Travel style– Luxury– On budget

u Duration(s) of stay(Date of departure)

29.02.2012 Page 3

Page 4: Global standard in travel medicine: a risk management ... · Travelers’ vaccines as solutions for travelers’ risks Global standard in travel medicine: a risk management perspective

Host factors – special risk groups

Page 429.02.2012

u infants, children

u senior travellers

u pregnant women

u pre-existing disease / condition– immuno compromized– AllergicConsider also: pre-existing immunity

29.02.2012 Page 4University of Zurich, Travelers' vaccines, Robert Steffen

Page 5: Global standard in travel medicine: a risk management ... · Travelers’ vaccines as solutions for travelers’ risks Global standard in travel medicine: a risk management perspective

Vaccine preventable diseases: first dimensionIncidence rate per month of infections among travelers in developing countries

100%

10%

1%

0.01%

0.001%

Malaria (overall West Africa)

Typhoid (South Asia, N/W/Central-Africa)

PPD conversion

Cholera

Influenza A or B

Typhoid (other areas)

Dengue infection (symptomatic)Animal bite with rabies risk

Tick borne encephalitis (rural Austria)

Legionella infection

Meningococcal disease

0.1%

Traveler’s diarrhea

0.0001%

Hepatitis A

Hepatitis B

HIV-infection

Japanese encephalitis

Fatal accident

Poliomyelitis

Malaria (overall Central America/Carib.)

29.02.2012 Page 5

Page 6: Global standard in travel medicine: a risk management ... · Travelers’ vaccines as solutions for travelers’ risks Global standard in travel medicine: a risk management perspective

The first and second dimension:Incidence rate per month PLUS severity of infections among travelers

Steffen R & Connor BA. J Travel Med 2005;12:26-35

Page 629.02.2012 University of Zurich, Travelers' vaccines, Robert Steffen

Page 7: Global standard in travel medicine: a risk management ... · Travelers’ vaccines as solutions for travelers’ risks Global standard in travel medicine: a risk management perspective

Third dimension in travel vaccines: costs

u Relevance: Luxury vs. backpacker

u Vaccine cost categories (varies by country):u Low: EPI, e.g. diphtheria / tetanus, poliomyelitis

u Intermediate: hepatitis A, typhoid, rabies intradermal

u High: Japanese encephalitis, ‚new‘ vaccines

u Consider: Risk situations

29.02.2012 Page 7University of Zurich, Travelers' vaccines, Robert Steffen

Page 8: Global standard in travel medicine: a risk management ... · Travelers’ vaccines as solutions for travelers’ risks Global standard in travel medicine: a risk management perspective

Fourth dimension: legal requirements

uRequired ++ Yellow fever± Meningococcal± Measles± Cholera

+++ WHO / EPI (+)+++ National vaccine plan

l Routine

l Recommended

Risk assessment —> priorities

Page 829.02.2012 University of Zurich, Travelers' vaccines, Robert Steffen

Page 9: Global standard in travel medicine: a risk management ... · Travelers’ vaccines as solutions for travelers’ risks Global standard in travel medicine: a risk management perspective

Yellow Fever (YF) endemic countries(reported cases, underreporting common!)

Page 929.02.2012 University of Zurich, Travelers' vaccines, Robert Steffen

Page 10: Global standard in travel medicine: a risk management ... · Travelers’ vaccines as solutions for travelers’ risks Global standard in travel medicine: a risk management perspective

University of Zurich, Travelers' vaccines, Robert Steffen

Destination Yellow fever infectionin unvaccinated persons

Yellow fever vaccine, serious adverse event (SAE)

Incidence per 100,000/wk

Death per 100,000/wk

YEL-AVD / -AND* per 100,000

1-99 y ≥60y

Fatal SAE* per 100,000

≥60yAge group

Subsah. Africa- endemic 23.8 12- epidemic 357 179 0.7 ≥5.3 ≥2South America (1.6**)- endemic 2.4 1.2- epidemic 35.7 17.9

Risk of yellow fever vs risk of vaccine(Khromava et al. 2005, Monath TP et al. 2005, Muñoz JM et al. JTM 2008;15:202-5)

YEL-AVD= yellow fever vaccine associated viscerotropic diseaseYEL-AND = yellow fever vaccine associated neurotropic disease* = all cases occurred in primary yellow fever vaccinees** = including other severe adverse reactions

Page 1029.02.2012

Page 11: Global standard in travel medicine: a risk management ... · Travelers’ vaccines as solutions for travelers’ risks Global standard in travel medicine: a risk management perspective

Yellow fever (YF) vaccination

Indicated ifRequired– direct: Tropical Africa, etc.– transit via infected areas– only by approved Centers, MDs

Recommended if considerable exposure in infected area

Info: - Travel Info Manual- WHO / ITH- US / CDC Yellow book- Embassies?

Page 1129.02.2012 University of Zurich, Travelers' vaccines, Robert Steffen

Page 12: Global standard in travel medicine: a risk management ... · Travelers’ vaccines as solutions for travelers’ risks Global standard in travel medicine: a risk management perspective

YF vaccine requirement (transit rule): from the Victoria Falls to Johannesburg

Page 12

Immunization required by South African authorities

Page 13: Global standard in travel medicine: a risk management ... · Travelers’ vaccines as solutions for travelers’ risks Global standard in travel medicine: a risk management perspective

Meningococcal diseaseCaused by the bacterium Neisseria meningitidis

– Most epidemics caused by serogroups A, B, C, W-135 and X– Spread from person to person

u Incidence is highest in the “African Meningitis Belt” (AMB) of sub-Saharan Africa

u Outbreaks have occurred inHajj pilgrims (until 2003)

u Symptomatic disease is fatal in 5–10% of cases

u Up to 20% have permanent neurological sequelae

WHO: International Travel and Health 2011, pp. 105-8. Map: http://gamapserver.who.int/mapLibrary/Files/Maps/Global_MeningitisRisk_ITHRiskMap.png

Meningococcal meningitis, countries at high risk, 2009

29.02.2012 Page 13University of Zurich, Travelers' vaccines, Robert Steffen

Page 14: Global standard in travel medicine: a risk management ... · Travelers’ vaccines as solutions for travelers’ risks Global standard in travel medicine: a risk management perspective

uRequired for pilgrims to Mecca (tetravalent vaccine to be used)

u ... should be considered for travellers to countries where outbreaks ... are known to occur, e.g.

u Sub-Saharan meningitis belt... (December - June)

u College students at risk

Meningococcal vaccine

Use tetravalent ACW135Y vaccine, monovalent C conjugate vaccine preferred only

in infants and college students**where tetravalent conjugate vaccine has not yet been licenced

Page 1429.02.2012 University of Zurich, Travelers' vaccines, Robert Steffen

Page 15: Global standard in travel medicine: a risk management ... · Travelers’ vaccines as solutions for travelers’ risks Global standard in travel medicine: a risk management perspective

Anecdotal cases of meningococcal disease in travelers, from 1996 (selection)Type of traveler Origin Location OutcomeChildrenPHLS. CDR Weekly 1996;6:191

UK, Germany Majorca, Spain 2 died, 2 recovered(2 children died in same hotel)

Students (2)Zuscheid et al. Euro Surveill 2008, Nov 6; Rapp C et al J Travel Med 2010;17:1-7

Swiss / French Germany 1 died, 1 recovered

AthleteCummiskey J et al. J Sports Med

Phys Fitness 2008;48:125-8

unknown Jaca, Spain(1500 athletes from 43 countries)

recovered

TouristAnonymous. NZZ 1 November 2006

Swiss Tirol, Austria died(only in public media)

JournalistWilder-Smith A & Goh KT. J Travel Med 2003;10:59-60 (W135)

UK Morocco > Japan> Singapore

recovered

BusinessmanLapadula G et al. Emerg Infect 2009;15:52-54

Italy Delhi, Chennai recovered

Page 1529.02.2012 University of Zurich, Travelers' vaccines, Robert Steffen29.02.2012 Page 15

Page 16: Global standard in travel medicine: a risk management ... · Travelers’ vaccines as solutions for travelers’ risks Global standard in travel medicine: a risk management perspective

Vaccine Child Adolescent Adult SeniorDipht/Tetanus/Pertussis +++ ++§ ++§ ++§Hepatitis B most c/u c/u (risk)Haemophilus influenzae B + (≤5 yrs) Ø Ø ØHuman Papilloma Virus Ø + (female) c/u ØInfluenza §, risk §, risk §, risk ++MMR +++ c/u (2 doses) c/u ØPneumococcal disease § risk risk +§Rotavirus § Ø Ø ØTuberculosis § Ø / c/u Ø ØVaricella § c/u c/u Ø

+ to +++ = routine (EPI), Ø = not indicated, c/u = catch-up if previously missed,§ = see national recommendations

Page 1629.02.2012 University of Zurich, Travelers' vaccines, Robert Steffen

Routine immunizations

Page 17: Global standard in travel medicine: a risk management ... · Travelers’ vaccines as solutions for travelers’ risks Global standard in travel medicine: a risk management perspective

Measles genotypes, SwitzerlandEpidemic with >5000 cases; 2006-11

N

EW

S0 50 100 150 Kilometers

D5B3A

Genotype

Courtesy: Prof. Ch. Aebi

Page 18: Global standard in travel medicine: a risk management ... · Travelers’ vaccines as solutions for travelers’ risks Global standard in travel medicine: a risk management perspective

Origin of the Swiss measles epidemic 2007-11 (mostly genotype D5) ?

Courtesy: Prof. Ch. Aebi

Page 19: Global standard in travel medicine: a risk management ... · Travelers’ vaccines as solutions for travelers’ risks Global standard in travel medicine: a risk management perspective

Swiss Exports: Measles 2006 / 10

courtesy Prof. Ch. Aebi29.02.2012

8 July 2010:• Passenger (23 mo/old) no-MMR• Flight Zurich - Boston• Diagnosis measles on arrival 8 July

Consequence 1:• 31 passengers exposed• 29/31 notified • Measles confirmed: 1 student

Consequence 2:• 270 students, teachers exposed• 2 non-immunes: Quarantine!

MMWR 2010;59:1073 (August 27)

Page 1929.02.2012

Page 20: Global standard in travel medicine: a risk management ... · Travelers’ vaccines as solutions for travelers’ risks Global standard in travel medicine: a risk management perspective

University of Zurich, Travelers' vaccines, Robert Steffen29.02.2012 Page 20

Measles in Japanese travelers

Measles outbreak associated with an international youth sporting event in the United States, 2007.„The index case occurred in a child from Japan aged 12 years.

Contact tracing among 1250 persons in 8 states identified 7 measles cases ... linking the outbreak to contemporaneous measles virus genotype D5 transmission in Japan.

Chen TH et al. Pediat Infect Dis 2010;29:794-800.See also: Takahashi H & Saito H. Measles exportation from Japan to the U.S. 1994-2006. J Travel Med 2008;15:82-6.

29.02.2012 Page 20

Page 21: Global standard in travel medicine: a risk management ... · Travelers’ vaccines as solutions for travelers’ risks Global standard in travel medicine: a risk management perspective

Page 2129.02.2012 University of Zurich, Travelers' vaccines, Robert Steffen

Page 22: Global standard in travel medicine: a risk management ... · Travelers’ vaccines as solutions for travelers’ risks Global standard in travel medicine: a risk management perspective

29.02.2012 Page 22University of Zurich, Travelers' vaccines, Robert Steffen

Influenza — trivial?

Page 23: Global standard in travel medicine: a risk management ... · Travelers’ vaccines as solutions for travelers’ risks Global standard in travel medicine: a risk management perspective

Influenza in travelersFollow-up study:Population: 1450 travelers to developing countries (1/1998 -3/ 2000)

Febrile illness: 289 (19.9%)

Two serum samples: 211 (73.0%) + 321 matched controls

Seroconversion for influenza virus infection (WHO CC London)

40 (67% with fever, 33% asymptomatic, 18 w/≥4x ab)

Incidence rate / 100 person-months: 1.0

Most frequent vaccine preventable infection!Mütsch M et al Clin Infect Dis 2005;40:1282-87

Page 2329.02.2012 University of Zurich, Travelers' vaccines, Robert Steffen

Page 24: Global standard in travel medicine: a risk management ... · Travelers’ vaccines as solutions for travelers’ risks Global standard in travel medicine: a risk management perspective

Large summertime outbreak of respiratory illnessu Cruise to Alaska, 1998u Doctor visits for ARI per 1000 tourists: 11.6u 5361 cases of ARI, 53% of ILIu 171 (3.2%) pneumoniau 4 deaths (all elderly)u Influenza A in 71%

Uyeki TM et al. Clin Infect Dis 2003;36:1095-1102Courtesy: Prof. Annelies Wilder-Smith, Singapore

Page 2429.02.2012 University of Zurich, Travelers' vaccines, Robert Steffen

Page 25: Global standard in travel medicine: a risk management ... · Travelers’ vaccines as solutions for travelers’ risks Global standard in travel medicine: a risk management perspective

Seasonal Influenza Vaccines

29.02.2012 University of Zurich, Travelers' vaccines, Robert Steffen Page 25

Year A/H3N2 A/H1N1 B2001/2N Moscow/10/99 New Caledonia/20/99 Sichuan/379/992002/3N same same Hongkong 330/012003/4N same same same2004/5N Fujian 411/02 same Shanghai 361/022005/6N California 7/04 same same2006/7N Wisconsin 67/05 same Malaysia 2506/042007/8N dito Solomon IsI/3/06 same2008 S Brisbane 10/07 same Florida 4/062008/9N same Brisbane 59/07 same2009/10N same same Brisbane 60/082010S Perth 16/09 California 7/09 same2010/11N

2011S

2011/12N

same

same

same

same

same

same

same

same

same

Page 26: Global standard in travel medicine: a risk management ... · Travelers’ vaccines as solutions for travelers’ risks Global standard in travel medicine: a risk management perspective

University of Zurich, Travelers' vaccines, Robert Steffen

WHO Map of HBV Risk Areas

Page 2629.02.201229.02.2012 Page 26

Page 27: Global standard in travel medicine: a risk management ... · Travelers’ vaccines as solutions for travelers’ risks Global standard in travel medicine: a risk management perspective

University of Zurich, Travelers' vaccines, Robert Steffen

Risk of hepatitis B transmission

10 - 15% in high-risk situation

Page 2729.02.201229.02.2012 Page 27

Page 28: Global standard in travel medicine: a risk management ... · Travelers’ vaccines as solutions for travelers’ risks Global standard in travel medicine: a risk management perspective

University of Zurich, Travelers' vaccines, Robert Steffen

Hepatitis B vaccinationVaccine to be considered for virtually all non-immunes… travelling to areas with moderate to high transmission:- Africa- Asia (excl. Japan, Singapore)- Latin America (excl. Argentina, Chile) - Eastern Europe, remote countries

Consider ’special risk groups’ but NOTE: >10% ’at risk’!

Contraindication:- Immunity by previous infection

WHO: International Travel and Health, Geneva 2011

Page 2829.02.2012

Hepatitis B vaccine does NOT prevent HIV / Aids!

29.02.2012 Page 28

Page 29: Global standard in travel medicine: a risk management ... · Travelers’ vaccines as solutions for travelers’ risks Global standard in travel medicine: a risk management perspective

WHO Map of HAV Risk Areas

Page 2929.02.2012 University of Zurich, Travelers' vaccines, Robert Steffen

Page 30: Global standard in travel medicine: a risk management ... · Travelers’ vaccines as solutions for travelers’ risks Global standard in travel medicine: a risk management perspective

Hepatitis A — impact

ON PUBLIC HEALTH� Epidemic: 352 Tourists (Germans) diagnosed 2004 after a stay in the Siva Grand Beach Hotel, Hurghada, Egypt

� Outbreaks in kindergardens, day-nurseries

� Outbreaks associated with food-handlers

� Clusters around adopted children, refugees

ON INDIVIDUAL PATIENT• Incapacitation 4-10 weeks• Case fatality rate

- over 40 years old 2.1%- over 60 years old 4.0%

Page 3029.02.2012 University of Zurich, Travelers' vaccines, Robert Steffen

Page 31: Global standard in travel medicine: a risk management ... · Travelers’ vaccines as solutions for travelers’ risks Global standard in travel medicine: a risk management perspective

University of Zurich, Travelers' vaccines, Robert Steffen

„all non-immune travellers to endemic areas“

„those at high risk strongly encouraged to accept vaccination“

„all travellers to, and all expatriates living in, moderately / highly endemic areas“

„travellers visiting areas of hepatitis A risk, particularly those visiting friends and relatives, long-term travellers and those visiting areas of poor sanitation“

„All susceptible persons traveling to or working in countries that have high or intermediate hepatitis A endemicity should be vaccinated“

Hepatitis A vaccination recommended for...

29.02.2012 Page 31

Australian Immunisation Handbook, 9th Edition 2008

Immunisation against Infectious Diseases, The Green Book 2007

CDC Health Information for International Travel, The Yellow Book 2010

International travel and health, WHO 2010

Page 32: Global standard in travel medicine: a risk management ... · Travelers’ vaccines as solutions for travelers’ risks Global standard in travel medicine: a risk management perspective

Page 32University of Zurich, Travelers' vaccines, Robert Steffen Page 32

Typhoid risk in travellersHigh risk-Destinations:

>0.2 pro 1000

Page 3229.02.2012

High risk-Travelers:l VFRl ‚Backpackers‘l Stay > 1 month

TF in Japanese travelers:Thapa R et al. (Nepal) J Travel Med 2010;17:199-200.

Page 33: Global standard in travel medicine: a risk management ... · Travelers’ vaccines as solutions for travelers’ risks Global standard in travel medicine: a risk management perspective

Typhoid fever vaccinationRecommended for:- Destination: High risk countries or areas - Duration of stay: > 1 month - Exposure: food or beverages away from

the usual tourist routes in developing countries

Particularly appropriate where antibiotic-resistance strains of S. typhi are prevalent

WHO: International Travel and Health, Geneva 2011, 126-8.See also: Takayama N. Kansenshogaku Zasshi 2005;79:254-9.

Page 3329.02.2012 University of Zurich, Travelers' vaccines, Robert Steffen

Page 34: Global standard in travel medicine: a risk management ... · Travelers’ vaccines as solutions for travelers’ risks Global standard in travel medicine: a risk management perspective

Rabies on Bali

124 human cases since 2008

Page 3429.02.2012 University of Zurich, Travelers' vaccines, Robert Steffen

Page 35: Global standard in travel medicine: a risk management ... · Travelers’ vaccines as solutions for travelers’ risks Global standard in travel medicine: a risk management perspective

Risk of rabies exposure in travelersu ANIMAL BITES with potential risk

- U.S. Peace Corps: 4.4% per year

- Swiss expatriates: 1.8% per yearBernard K & Fishbein DB. Vaccine 1991;9:833-6Hatz CF et al. Vaccine 1995;13:811-5 Pandey P et al. J Travel Med 2002;9:127-31

u Postexposure prophylaxis (PEP)- STRESS! Rabies-IG difficult to find outside big centers- Number unknown!

u Fatal rabies in travelers: 42 (1990-2010)Malerczyk C et al. J Travel Med 2011;18:402-7.Yamamoto S et al. J Travel Med 2008;15:372-4.

29.02.2012 Page 35University of Zurich, Travelers' vaccines, Robert Steffen

Page 36: Global standard in travel medicine: a risk management ... · Travelers’ vaccines as solutions for travelers’ risks Global standard in travel medicine: a risk management perspective

Particular risk for rabies

Destination:India (15’000-20’000�)

Particularly, travel related:- Children*- Bicycle*/motorbike riders- Trekkers, hikers* (e.g. Nepal)- Prolonged stay*- Professionals with exposure*- Spelunkers*

* WHO: International Travel and Health, Geneva 2011

University of Zurich, Travelers' vaccines, Robert Steffen29.02.2012 Page 36

Page 37: Global standard in travel medicine: a risk management ... · Travelers’ vaccines as solutions for travelers’ risks Global standard in travel medicine: a risk management perspective

„Pre-exposure prophylaxis for those planning a visit to rabies endemic country, especially if the visited area is farfrom urban centres, where...“

„Rabies pre-exposure vaccine should generally be given to adults and children who are at risk of rabies including thoseu travelling to remote areas where medical care is not readily availableu undertaking higher risk activities (e.g. cycling, running)u travelling for long periods through rabies endemic countriesu at occupational risk e.g. vets, animal handlers, and laboratory...“

„... rabies vaccine may be recommended based on u local incidence, u ... availability of appropriate anti-rabies biologicals,u intended activity and u duration of stay / repeat travel...“

Rabies immunization recommendations

29.02.2012 Page 37University of Zurich, Travelers' vaccines, Robert Steffen

Page 38: Global standard in travel medicine: a risk management ... · Travelers’ vaccines as solutions for travelers’ risks Global standard in travel medicine: a risk management perspective

JE vaccine recommendations, travelersTraditional:- Stays in endemic zones ≥ 2-4 weeks- With RURAL overnight staysExample: Agronomics student preparing Ph. D. thesis, living

close to rice fields

NEW (2010): no more minimal stay- WHO: Extensive outdoor exposure: Camping, hiking, bicycle, outdoor occupational activities in rural areas

- CDC: Duration of stay > 1 month or short-term (< 1 month) if travel

- outside urban area- Area with outbreak- Uncertain specific destination, activities, duration

WHO: International Travel and Health, Geneva 2011CDC: ‘Yellow book’ 2012,wwwnc.cdc.gov/travel/yellowbook/2012/chapter-2/japanese-encephalitis.aspx

Do we protect all at risk? Consider:- Cumulative exposure

- Request for maximum protection

University of Zurich, Travelers' vaccines, Robert Steffen29.02.2012 Page 38

Page 39: Global standard in travel medicine: a risk management ... · Travelers’ vaccines as solutions for travelers’ risks Global standard in travel medicine: a risk management perspective

Cholera

90% of episodes are mild or moderateand difficult to distinguish from other types of travellers diarrhea — usually not diagnosed

Ref. WHO Fact sheet No 107; Sack, Lancet, 2004; CDC - Center for Disease Control and Prevention

University of Zurich, Travelers' vaccines, Robert Steffen29.02.2012 Page 39

Page 40: Global standard in travel medicine: a risk management ... · Travelers’ vaccines as solutions for travelers’ risks Global standard in travel medicine: a risk management perspective

www.gamapserver.who.int/mapLibrary/Files/Maps/World_CholeraCFR(WER)_CUM2007_colour.png

Page 4029.02.2012 University of Zurich, Travelers' vaccines, Robert Steffen

Page 41: Global standard in travel medicine: a risk management ... · Travelers’ vaccines as solutions for travelers’ risks Global standard in travel medicine: a risk management perspective

Recommended immunizations in non-immune travelers for a stay in a developing countryExpert group WHO CATMAT CDC NaTHNaC NHMRC JAPAN

World Canada USA UK Australia Available

REQUIRED- Yellow fever ** ** ** ** ** +ROUTINE- Diphtheria/tetanus/MMR *** *** *** *** *** +- Poliomyelitis ** ** ** ** ** +- Hepatitis B *** *** *** * *** +RECOMMENDED- Hepatitis A *** *** *** ***/* ***/* +- Typhoid fever * * * * * ±- Rabies * * * * * +- Meningococcal disease * * * * * ±- Japanese encephalitis * * * * * +- Tick borne encephalitis * * * * * —- Tuberculosis * -/* - * * +- Cholera * * -/* * * ±- Influenza * * *** * ? +*** = all, ** = all when visit in endemic country, * = risk group only, - = none

Page 42: Global standard in travel medicine: a risk management ... · Travelers’ vaccines as solutions for travelers’ risks Global standard in travel medicine: a risk management perspective

Condition RestrictionAge- Infants- Elderly

Some vaccines not approvedConsider weak immune responseYF vaccine only if clearly at risk

Pregnancy- Live vaccines

- Inactivated vaccines

BCG, MMR, Varicella contraindicatedYF vaccine only if high riskYes, if no risk (safety often not determined)

Chronic medical problems- impaired immunity, incl.- steroids, methotrexate,TNFa, interferon

Caution with live vaccines if low CD4Consider weak immune response

Many contraindications

Finally: risks of travel vaccines —Caution and Contraindications

Page 4229.02.2012 University of Zurich, Travelers' vaccines, Robert Steffen

Page 43: Global standard in travel medicine: a risk management ... · Travelers’ vaccines as solutions for travelers’ risks Global standard in travel medicine: a risk management perspective

Page 4329.02.2012 University of Zurich, Travelers' vaccines, Robert Steffen

Conclusions: what priorities?

1. Incidence: Influenza

2. Impact: Neurotropic IDs

3. Legal:Yellow fever

4. Costs vs. risk analysisRabies

Page 44: Global standard in travel medicine: a risk management ... · Travelers’ vaccines as solutions for travelers’ risks Global standard in travel medicine: a risk management perspective

29.02.2012 Page 44University of Zurich, Travelers' vaccines, Robert Steffen

Page 45: Global standard in travel medicine: a risk management ... · Travelers’ vaccines as solutions for travelers’ risks Global standard in travel medicine: a risk management perspective

Tuberculosis vaccination (BCG)(EPI in many national recommendations)

Indicated for:

To be considered* for:

(*US/CDC: no BCG!)

Not for travel

u infants <6 months traveling to (remote) high-risk areas

u health workers

WHO: International Travel and Health, Geneva 2011Rieder H. Clin Infect Dis 2001;33:1393-96

Page 4529.02.2012 University of Zurich, Travelers' vaccines, Robert Steffen

Page 46: Global standard in travel medicine: a risk management ... · Travelers’ vaccines as solutions for travelers’ risks Global standard in travel medicine: a risk management perspective

Global Neisseria meningitidisSerogroup Distribution

References upon request.

CANADA1

USA2

EUROPE4

BRAZIL3

AFRICAN MENINGITIS

BELT6

JAPAN9

TAIWAN8

AUSTRALIA10 NEWZEALAND11

Represents serogroups not defined for each individual country

YW-135B CA X

23% 59%

35%

31%

25%

25%

68%

ARGENTINA3

52%37%

69%14%

17%

78%

SOUTH AFRICA7

47%10%

11%

50%35%

57%21%

84%11%

82%

14%

TURKEY5

35%

18%

COLOMBIA3

29%29%

33%

29.02.2012 Page 46University of Zurich, Travelers' vaccines, Robert Steffen

Page 47: Global standard in travel medicine: a risk management ... · Travelers’ vaccines as solutions for travelers’ risks Global standard in travel medicine: a risk management perspective

Worldwide WC-rCTB (Dukoral®) marketing

Hill DR et al. Lancet Infect Dis 2006;6:361-73

University of Zurich, Travelers' vaccines, Robert Steffen29.02.2012 Page 47

Page 48: Global standard in travel medicine: a risk management ... · Travelers’ vaccines as solutions for travelers’ risks Global standard in travel medicine: a risk management perspective

Efficacy of WC/rBS vaccine against choleraIn >6y/o in first 12 months: PE 76% (95% CI 60-85)

AND additional herd immunity in BangladeshAli M et al. Lancet 2005;366:7-9

In >2y/o in first >6 months: PE 78% (95% CI 39-92)

in Beira, MozambiqueLucas ME et al. N Engl J Med 2005;352:757-67

NOTE: No longer available worldwide

uCVD103HgR (Orochol®, Mutachol® / BernaBiotech)u ‘Traditional’ injectable vaccine

University of Zurich, Travelers' vaccines, Robert Steffen29.02.2012 Page 48

Page 49: Global standard in travel medicine: a risk management ... · Travelers’ vaccines as solutions for travelers’ risks Global standard in travel medicine: a risk management perspective

Structural, functional and immunological similarities of:

LTB (ETEC) vs. CTB (Cholera)

University of Zurich, Travelers' vaccines, Robert Steffen29.02.2012 Page 49

Page 50: Global standard in travel medicine: a risk management ... · Travelers’ vaccines as solutions for travelers’ risks Global standard in travel medicine: a risk management perspective

Efficacy of WC/rCTB oral CHOLERA vaccine againstheat labile enterotoxigenic E. coli (LT-ETEC)Basing on similarities some evidence on efficacy against LT-ETEC from:

uBangladesh: PE 67% (95% CI 16-87, p=0.02)

uFinns in Morocco: PE 60%PE against ETEC+Salmonella 82%(!)

uUS in Mexico: PE50% (7d after dose 2, given in Mexico!)

Clemens JD et al. J Infect Dis 1988;158:372-7Peltola H et al. Lancet 1991;338:1285-9Scerpella E.G. et al. J Travel Med 1995;2:22-7

University of Zurich, Travelers' vaccines, Robert Steffen29.02.2012 Page 50

Page 51: Global standard in travel medicine: a risk management ... · Travelers’ vaccines as solutions for travelers’ risks Global standard in travel medicine: a risk management perspective

Estimated benefit of WC-rCTB vaccine (Dukoral®) in travelers

Travelers with

TD

!

1 2 3 4 5 65%

Steffen R et al. In Travelers’ diarrhea, Ericsson et al. Eds. BC Decker, Hamilton, London 2003University of Zurich, Travelers' vaccines, Robert Steffen29.02.2012 Page 51

Page 52: Global standard in travel medicine: a risk management ... · Travelers’ vaccines as solutions for travelers’ risks Global standard in travel medicine: a risk management perspective

Routine schedule for travel vaccines

1st CONSULTATION 2nd CONSULTATION- Yellow fever *2nd / 3rd dose- Diphtheria / Tetanus if necessary to- Hepatitis A complete primary- Typhoid (Ty 21a / Vi) vaccination- Poliomyelitis- Hepatitis B*, A+B*- Rabies*- Meningococcal meningitis- Japanese encephalitis*- MMR, etc.

ideally

DepartureWeeks priorto departure

6 5 4 3 2 1 0

REQUIREDROUTINE

RISKGROUPS

Page 5229.02.2012 University of Zurich, Travelers' vaccines, Robert Steffen

Page 53: Global standard in travel medicine: a risk management ... · Travelers’ vaccines as solutions for travelers’ risks Global standard in travel medicine: a risk management perspective

Application of vaccines in travelersGENERAL RULESu store as recommended by manufactureru shake well before useu administer as recommended IM, SC, IDu select deltoid in adults and children >1 y/o,

anterolateral thigh in infantsu cleanse skin with antiseptic, ideally wait 5 minutes

NOTEu travel industry NOT reliable for vaccine selectionu vaccine manufacturers NOT reliable for indication

University of Zurich, Travelers' vaccines, Robert Steffen29.02.2012 Page 53